Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by SanFrancisco99on Mar 14, 2015 8:27pm

157 Views

Post# 23521919

RE:RE:RE:Amazing Few Weeks: Winter Surprise for RVX

Very well put, Sir. Thank you for that.

I agree completely. I think there's a very bright future for RVX now that we have a very compelling new course ahead of us.

What's the true value of the formula today? I still think it is a multiple of Friday's stock price.

It will be interesting to see where it ends up by first (reMACE) dosing this summer. Certainly above $2. That's a safe bet I think. I think it will be much higher than that.

Bullboard Posts

Consumer advocacy law firm investigates Microsoft over X-Box data concerns